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Available online 25 March 2019Background: Neonatal screening for Pompe disease is complicated by difficulties in predicting symptom onset in
patientswith the common c.-32-13TNG (IVS1) variant/null (i.e. fully deleterious) acidα-glucosidase (GAA) geno-
type. This splicing variant occurs in 90% of Caucasian late onset patients, and is associated with a broad range of
symptom onset.
Methods: We analyzed a cohort of 143 compound heterozygous and 10 homozygous IVS1 patients, and we
assessed ages at symptom onset, the presence of cis-acting single nucleotide variants (SNVs), and performed
splicing analysis and enzyme activity assays.
Findings: In compound heterozygous IVS1 patients, the synonymous variant c.510CNT was uniquely present on
the IVS1 allele in 9/33 (27%) patientswith childhood onset, butwas absent from110patientswith onset in adult-
hood. GAA enzymeactivitywas lower infibroblasts frompatientswho contained c.510CNT than itwas in patients
without c.510CNT. By reducing the extent of leaky wild-type splicing, c.510CNT modulated aberrant splicing
caused by the IVS1 variant. The deleterious effect of c.510CNT was also found in muscle cells, the main target
cells in Pompe disease. In homozygous IVS1 patients, the c.510CNT variant was absent in 4/4 (100%) asymptom-
atic individuals and present in 3/6 (50%) symptomatic patients. In cells fromhomozygous IVS1 patients, c.510CNT
caused reduced leaky wild-type splicing.
Interpretation: c.510CNT is a genetic modifier in compound heterozygous and homozygous IVS1 patients. This
finding is important for neonatal screening programs for Pompe disease.
Fund: This work was funded by grants from Sophia Children's Hospital Foundation (SSWO, grant S17–32) and
Metakids (2016–063).
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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c.510CNT1. Introduction
Pompe disease, ametabolicmyopathy caused by lysosomal glycogen
accumulation, results in progressive vacuolization of muscle cells.
Patients with the most severe classic infantile form present withs, Erasmus University Medical
. Pijnappel).
. This is an open access article undersymptoms shortly after birth and, if left untreated, die from cardiorespi-
ratory insufficiency within the first year of life. Patients with onset in
childhood or adulthood become wheelchair and/or ventilator depen-
dent at some point in their life [1]. Pompe disease is a monogenic auto-
somal recessive disorder caused by disease-associated variants in the
acid α-glucosidase (GAA) gene. Over 400 disease-associated variants
are known and described in the Pompe mutation database (www.
pompecenter.nl). Whereas classic infantile patients carry two fully
deleterious GAA variants, those with onset in childhood or adulthood
usually carry one fully deleterious variant in combination with a milderthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Many reports fromour owngroup aswell as frommany colleagues
have been published on the clinical heterogeneity of patients with
late onset Pompe disease that carry the common c.-32-13TNG
(IVS1) variant in the acid α-glucosidase (GAA) gene. Onset of
symptoms can vary from the age of 0 to N60 years, even for pa-
tientswith identicalGAA disease-associated variants. This has re-
sulted in the hypothesis that modifying factors for Pompe disease
exist.
Added value of this study
Our findings present the first genetic modifier identified in Pompe
disease that can explain why certain compound heterozygous
IVS1 patients develop symptoms early in life and why certain ho-
mozygous IVS1 patients develop symptoms at all. This is impor-
tant for newborn screening programs, for genetic counseling,
and for deciding when to start with enzyme replacement therapy
treatment.
Implications of all the available evidence
We identified a variant that so far has often not been reported in
standard DNA diagnostics. However, it is a simple DNA test that
can be included in standard diagnostics. This is important to en-
sure a timely start of treatment before irreversible muscle damage
has occurred. It will also provide important information for pa-
tients and their parents that participate in newborn screening pro-
grams, because at present the diagnosis of late onset Pompe
disease poses much uncertainty on how and when this diagnosis
will impact their lives. A more accurate prediction contributes to
better genetic counseling.
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hood or adulthood carry the c.-32-13TNG (IVS1) variant on one allele in
combination with a deleterious variant on the second allele (Suppl.
Table S1) [2–13]. However, symptom onset in these patients varies
broadly, ranging from b1 to 62 years of age. This suggests the possibility
that unidentified modifying factors are able to modulate age at symp-
tom onset [5,6,14–18]. This is also indicated by the relatively low fre-
quency of patients with the homozygous IVS1 genotype, suggesting
that many remain asymptomatic [11,17,19,20]. The genetics of Pompe
disease is explained in more detail in the supplementary text.
Since 2006, enzyme replacement therapy (ERT) has been available
for Pompe disease. ERT in these patients improves survival and motor
function, normalizes left ventricular cardiac hypertrophy, and stabilizes
respiratory capacity [21]. To enable fast diagnosis and early treatment,
newborn screening (NBS) programs have been introduced in a number
of countries in Asia, North America and Europe [22]. Such programs
have shown that most patients have a genotype consistent with the
late onset form of Pompe disease, and that this complicates the predic-
tion of disease onset and severity, and also the timing for starting ERT
treatment.
As these findings have increased the need to identify factors that can
modulate the onset of Pompe disease, we aimed to identify a putative
modifier in patients with the common IVS1 variant. Genomic DNA anal-
ysis of 153 patients with Pompe disease that carry the IVS1 variant was
performed using IVS1 allele-specific PCR. This resulted in the identifica-
tion of the c.510CNT variant to be exclusively present on the IVS1 allelein a subset of patients. This variant was only identified in compound
heterozygous IVS1 patients with childhood onset of symptoms. It was
also identified in 3 out of 6 symptomatic patients that were homozy-
gous for IVS1. RT-(q)PCR analysis showed that the variant negatively
influences pre-mRNA splicing in the context of the IVS1 splicing variant,
resulting in lowered expression of residual full-length GAAmRNA and
GAA enzymatic activity. These findings are important for the estimation
of age at symptom onset and for deciding when to start ERT treatment.
Reports on the presence of c.510CNT should be included in the genetic
diagnostic analysis of Pompe disease.
2. Materials & methods
2.1. Patients
Patients enrolled in this study were all diagnosed with Pompe dis-
ease on the basis of GAA enzyme deficiency and the presence of two
disease-associated variants in the GAA gene, at least one of which was
c.-32-13TNG. One hundred thirty-one compound heterozygous patients
enrolled in this study had a confirmed fully deleterious variant on the
second allele that did not produce any functional GAA enzymatic activ-
ity, as determined on the basis of clinical information (see www.
pompecenter.nl). Nine patients contained a deleterious GAA variant on
the second allele based on in silico prediction, while for three patients
the disease-associated variant on the second allele was not identified.
There was no preferential enrichment of patients based on the
disease-associated variant on the 2nd allele in any of the groups (child-
hood onset, adult onset, presence or absence of c.510CNT) analyzed.
RT-PCR analysis was restricted where possible to patients that had a
nonsense or frameshift variant on the second allele. We were unable
to avoid this for the analysis of one patient (patient 16) which had an
in-frame deletion of exon 18. Patients' age at symptom onset was deter-
mined by experienced clinicians on the basis of the description of the
first symptoms. Guidelines for determining symptom onset were used
as described in van der Ploeg et al., 2017 [23]. Briefly, symptomatic pa-
tients had skeletalmuscle and/or respiratory involvement. In patients at
Erasmus MC, age at symptom onset ranged from 0 to 67 years. Child-
hood onset patients are patients younger than 18 years of age at onset
of disease who do not have hypertrophic cardiomyopathy. Adult onset
patients are patients that are 18 years of age or older at onset of disease.
Biopsies from skin obtained using the punching method as described
[24]. Openmuscle biopsies were taken as described previously [19]. Pa-
tients analyzed in more detail in this study are listed in Supplementary
Tables S2 and S3. All patients provided informed consent. Analysis of the
patients analyzed in this studywas approved by themedical ethics com-
mittee of the participating institutes.
2.2. Allele-specific PCR and sequencing
DNA was isolated from either fibroblasts, leukocytes or myoblasts.
Allele-specific primers were designed based on the sequence surround-
ing the c.-32-13TNG variant with either T or G as the last nucleotide of
the primer and the requirements stated in the guidelines for each PCR
kit (see below). Two different PCR reactions were performed to obtain
allele specific results upstreamand downstreamof the c.-32-13TNGvar-
iant. Amplification of a region of 3 kilobases (kb) upstream of IVS1
required an optimized protocol using the Advantage GC2 PCR kit
(Clontech). Amplification 1 kb downstream of IVS1 was performed
using a standard PCR protocol. Sanger sequencing of the amplified prod-
ucts was performed using a ABI3730XL DNAAnalyzer andwas analyzed
for the presence of single nucleotide variants (SNVs)with ApE software.
2.3. RT-PCR
RT-PCR and RT-qPCR measurements were conducted as previously
described [25]. In brief, cells were harvested using the standard protocol
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(Qiagen). cDNA was generated using the iScript™ cDNA synthesis kit
(Bio-Rad) with 500 ng input per reaction. RT-PCR was performed
using the Advantage GC 2 kit (Clontech). RT-qPCR analysis was per-
formed using iTaq™ universal SYBR® Green Supermix (Bio-Rad) with
a CFX96 RT-system (Bio-Rad). RT-qPCR data were normalized relative
to beta-actin expression. PCR primers are listed in Supplementary
Table S4.
2.4. GAA enzymatic activity assay
The enzymatic activity of GAA in fibroblasts was determined as
described using a one-step protocol with 4-methylumbelliferone-α-d-
glucopyranoside (4-MU) (Sigma) as a substrate [16]. Protein lysates
were incubated for one hour, and fluorescence was measured at
365/448nm with a Varioskan™ system (Thermo-Fisher). Protein con-
centration of the lysates was determined using the BCA protein assay
(Pierce) performed as instructed in the protocol. Samples of Fig. 2C
were measured at the diagnostic department of the Erasmus MC using
a standardized protocol. All other samples were measured on research
basis and were normalized using individual 14 as an internal control.
2.5. Minigene
The minigenes were generated by site directed mutagenesis of
a pcDNA3.1 construct containing the genomic region of GAA exonFig. 1. Allele frequencies of SNVs around GAA IVS1. (A) Cartoon of the genomic region of GAA
highlighted in red (Supplementary Table S4). Exonic regions are highlighted as red boxes, an
and allele frequencies (MAF was obtained from gnomAD: http://gnomad.broadinstitute.org/).1 to 3 (GRCh38/hg38, chr17:80,101,086-80,105,998), according to
the manufacturer's protocol (QuikChange® II Site-Directed Muta-
genesis, Agilent, primers Suppl. Table S4) [29]. Minigenes were
transfected in HEK293T cells using Lipofectamine 2000 (Life Tech-
nologies) according to the manufacturer's protocol (per sample in
12-well format: 4 μl Lipofectamine and 1.6 μg plasmid DNA). Two
days after transfection, RNA was isolated using the RNeasy® mini
kit (Qiagen), and 800 ng of total RNA was reverse transcribed with
iScript™ (Bio-Rad). RT-(q)PCRs were performed as described
above. RT-qPCR data were normalized relative to Neomycin expres-
sion, which is constitutively expressed from the pcDNA3.1 vector, to
normalize for transfection efficiency.2.6. Statistics
Analyses were performed using the R statistical package, ver-
sion 3.4.3. To correct for the non-random distribution of the data
and familial connections, a Generalized Estimating Equation
(geepack package in R) was used to analyze the differences in
age at symptom onset between the patient groups with or without
the c.510CNT variant present on the IVS1 allele. All other statistical
analyses were performed using the standard t-test (random distri-
bution) or the Wilcoxon test (non-random distribution). All biolog-
ical data is shown using the average ± SD of three biological
replicates.spanning exon 1–3. Primers used for allele-specific amplification of the IVS1 allele are
d introns are indicated by lines. (B) List of 21 SNVs in GAA exons 1–3 with RS-numbers
Fig. 2. Association of c.510CNT with age at symptom onset and GAA enzymatic activity in
compound heterozygous IVS1 patients. (A) Distribution of ages at symptom onset in
compound heterozygous IVS1 patients with c.510CNT (red symbols) and without
c.510CNT (green symbols). Each dot in the graph represents one patient. The dashed red
line indicates the cut-off age of 18 years between patients with childhood onset and
adult onset of symptoms. (B) Median age at symptom onset in compound heterozygous
IVS1 patients with and without c.510CNT. *** p b 0.001. (C) GAA enzymatic activity in
fibroblasts from compound heterozygous IVS1 patients with and without c.510CNT. ** p
b 0.01.
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The IVS1 variant is located at−13 nucleotides (nt) of GAA exon 2 in
the polypyrimidine (pY) tract (Fig. 1A). GAA exon 2 contains the trans-
lation initiation codon, is relatively large (546 nt), and is preceded by an
intron of 2664 nt. We hypothesized that cis-acting variants might be
present near the IVS1 variant that modulate the activity of the IVS1 al-
lele. To test this, we used long-range allele-specific PCR and Sanger
sequencing of a 4.4 kb region comprising exon 1–3. In a cohort of 143
compound heterozygous IVS1 patients that contained a deleterious var-
iant on the second allele, we identified 21 SNVs (Fig. 1B). Interestingly,
all but onewere located on non-IVS1 alleles, except for the synonymous
variant c.510CNT,whichwas found in a subset of patients exclusively on
the IVS1 allele. The c.510CNT variant was found in 9 patients, all of
whom had symptom onset in childhood (see Table S2 for patient de-
tails). While c.510CNT occurred in combination with the IVS1 variant
in 9/33 (27%) of the population of IVS1 patients with childhood onset,
it occurred in 0/110 (0%) of patients with symptom onset in adulthood
(Fig. 1B). The c.271GNA variant (GAA2; pD91N), which has previously
been reported to lower the affinity of GAA for glycogen [26], was absent
from the IVS1 allele, and occurred in only 1 adult patient on the non-
IVS1 allele, indicating that its frequency is low and that it cannot ac-
count for phenotypic differences within our cohort. Fig. 2A shows the
ages at symptom onset in compound heterozygous IVS1 patients with
and without c.510CNT. Median age at symptom onset was 2.5 years in
patients with c.510CNT, against 31 for patients without c.510CNT
(p ≤.001) (Fig. 2B). Similar results were found for age at diagnosis
(5.4 years in those with c.510CNT versus 37 in those without) (Suppl.
Fig. S1A and B). To illustrate that the disease-associated variant on the
second allele did not play a role in phenotypic heterogeneity, we ana-
lyzed 57 patients that all shared the same IVS1/c.525del GAA genotype.
These patients also variedwidely in age at symptom onset: two patients
that contained c.510CNT had symptomonset at 1 and 6.5 years,while 55
patients without c.510CNT had symptom onset ranging from
0.5–61 years (Suppl. Fig. S1C). The GAA enzymatic activity in fibroblasts
from compound heterozygous patients with c.510CNT was lower than
in patients without c.510CNT (Fig. 2C). We conclude that c.510CNT is
linked to the IVS1 variant and, when present, is associated with early
onset of symptoms and low GAA enzymatic activity.
The IVS1 variant affects pre-mRNAsplicing and induces full or partial
skipping of GAA exon 2 (products splice variant (SV) 2 and SV3 in
Fig. 3A, respectively) [15,25,27,28] andutilization of a pseudoexon in in-
tron 1 (products SV5 and SV6) [29]. It also allows a low level (10–15%)
of leaky wild-type splicing (product N). The c.510CNT variant is located
close to the cryptic splice site in exon 2 and the canonical splice donor of
exon 2 (Fig. 3B), suggesting that it might affect splicing. To test this, we
performed flanking exon RT-PCR analysis of primary fibroblasts ob-
tained from patients with and without c.510CNT (Fig. 3C). Exon 2 splic-
ing was altered in cells that contained c.510CNT: expression of N and
SV3 were lowered relative to cells that lacked c.510CNT. To quantify
these results, we performed RT-qPCR analysis using primers that specif-
ically amplified splice isoforms. Relative to cells that lacked c.510CNT,
this showed the following: decreased expression of normal splicing
(product N) (Fig. 3D) and cryptic splicing (product SV3)(Fig. 3E); un-
changed expression of fully skipped product (SV2) (Fig. 3E); and in-
creased SV2/SV3 ratios (Fig. 3F) in cells that contained c.510CNT (see
Suppl. Tables S2 and S3 for patient details). Importantly, the decreased
expression of N resulted in a significant decrease of GAA enzymatic ac-
tivity in these patients (Suppl. Fig. S2). To establish that these changes
were caused solely by c.510CNT rather than by other genetic variations,
we used a minigene system in which the genomic region of GAA exons
1–3 was cloned in an expression vector (Suppl. Fig. S3A) [29]. After
transfection into HEK293T cells, splicing was analyzed by PCR. In the
minigene system, the IVS1 variant reproduced the aberrant splicing
seen endogenously in fibroblasts [29]. Flanking exon RT-PCR analysis
showed that, when combined with the IVS1 variant, the c.510CNTvariant changed the splicing pattern of exon 2 (Suppl. Fig. S3B). RT-
qPCR analysis indicated that c.510CNT reduced expression of N (Suppl.
Fig. S3C) and SV3 (Suppl. Fig. S3D), and increased expression of SV2
(Suppl. Fig. S3D) and SV2/SV3 ratios (Suppl. Fig. S3E). In the minigene
lacking IVS1, c.510CNT did not change expression of N (Suppl.
Fig. S3C). We conclude that, by lowering the extent of leaky wild-type
splicing, c.510CNT modulates the aberrant splicing caused by IVS1, and
that c.510CNT in the absence of IVS1 does not affect wild-type splicing.
The enzymatic activity of GAA in compound heterozygous patients is
derived from the IVS1 allele via leaky wild-type splicing, which pro-
duces 10–15% of normal mRNA transcript and full-length GAA protein.
Homozygous IVS1 patients should have twice the amount of this activ-
ity, reaching 20–30%, which, using the assay conditions employed here,
would be above the disease threshold. Consistent with this fact, only
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our cohort 10 unrelated individuals homozygous for IVS1 were present
(Fig. 4A): six patients developed symptoms at a median age of
48.5 years (range 12–59 years); five patients (18–22) have been de-
scribed previously [19]; two individuals currently aged 38 and
87 years are asymptomatic (25 and 26); and two individuals currently
aged 1 and 2 year (23 and 24) were diagnosed from NBS programs
and are asymptomatic (Fig. 4A). Sanger sequencing revealed that 3/6
(50%) symptomatic homozygous IVS1 patients carried c.510CNT: pa-
tients 17 and 18 carried c.510CNT at homozygous state, and patient 19
carried it at heterozygous state (Fig. 4A). None of the asymptomatic pa-
tients carried c.510CNT. In fibroblasts from homozygous IVS1 patients,
c.510CNT caused reduced normal splicing (product N) and an increased
SV2/SV3 ratio, as it did in fibroblasts from compound heterozygous IVS1
patients (Fig. 4B–E). The GAA enzyme activity in fibroblasts from the
homozygous IVS1 patient (patient 17 in Fig. 4F) who carried c.510CNT
was in the patient range (16 nmol/h/mg protein), whichwas consistent
with the low expression of product N and the development of symp-
toms. Patient 20, who was homozygous for IVS1 but did not carry
c.510CNT, also had GAA enzyme activity in the patient range (17
nmol/h/mg protein), which was consistent with the development of
symptoms. It is likely that another putative modifying factor plays a
role in this patient. These findings indicate that c.510CNT accelerates
thedevelopment of symptomsbyworsening splicing outcome in homo-
zygous IVS1 patients in the same way as in compound heterozygous
IVS1 patients.
Pre-mRNA splicing can be cell-type dependent. Because skeletal
muscle is the tissue most affected in Pompe disease, we examined the
effect of c.510CNT on splicing in muscle cells. Myoblasts were available
from three patients (Fig. 5A). The first was patient 16, who was com-
pound heterozygous for IVS1 and lacked c.510CNT, but whose second
allele contained the c.2481 + 102_2646 + 31del (delex18) variant. As
this is an in-frame deletion of exon 18 that produces normal levels of
a truncated mRNA transcript (translated into an inactive GAA protein),
it produces high levels of product N, which obscured analysis of product
N from the IVS1 allele (Fig. 5B). The second patient was patient 4, who
was compound heterozygous for IVS1 and c.510CNT, in which the
second allele carried the c.1548GNA nonsense variant leading to
nonsense-mediated decay of mRNA produced from this allele [25].
The third, patient 18, was homozygous for IVS1 and c.510CNT. RT-PCR
analysis in these three patients showed that the presence of c.510CNT
was associated with the characteristic splicing pattern observed in fi-
broblasts, inwhich expression of SV3 is reduced (Fig. 5A). RT-qPCR anal-
ysis confirmed that SV3 expression was reduced and that the ratio of
SV2/SV3 was increased in cells that contained c.510CNT (Fig. 5C and
D). In myoblasts, the c.510CNT variant was associated with lower GAA
enzyme activity in the compound heterozygous IVS1 patients (compare
patient 16 and 4), while the activity in the homozygous IVS1 patient
(patient 18) was well within the patient range (Fig. 5E). We noted
that the expression levels of exon 2 splicing products N, SV2, and SV3
were higher in patient 4 compared to patient 16, although their GAA en-
zyme activities were similar. We speculate that this might indicate dif-
ferences in mRNA turnover, but further experiments are required to
address this. We conclude that the deleterious effect that c.510CNT has
on the aberrant splicing caused by IVS1 in myoblasts is similar to its
effect in fibroblasts.Fig. 3. c.510CNTworsens splicing outcome in compound heterozygous IVS1patients. (A) Left: RT
heterozygous IVS1 patient (IVS1). The second allele in this patient did not producemRNA.M ind
Numbered boxes represent canonical exons. Unnumbered boxes represent facultative exons or
derived from utilization of the cryptic splice site at c.487 (in brown). Dotted lines represent in
(B) Position of c.510CNT in GAA exon 2. Positions of the cryptic and canonical splice sites of e
gray box represent the pseudoexon in intron 1. Dotted lines represent introns. (C) RT-PCR an
and without c.510CNT. Splice products N, SV6, SV5, SV3 and SV2 are indicated on the right. *:
and listed in Supplementary Tables S2 and S3. (D) As (C), but now analyzed using RT-qPCR
aberrant splice products SV2 and SV3. (F) Ratio of SV2/SV3. In healthy control cells, expressio
(n= 3 biological replicates). * = p b 0.05, *** = p b 0.001.4. Discussion
The most frequent disease-associated variant in the Caucasian
population is the IVS1 variant, which occurs in a large majority
(90%) of childhood and adult onset patients [2–13]. Previous work
has identified 12 haplotypes in Caucasian IVS1 patients based on
17 single nucleotide polymorphisms that were distributed over the
entire GAA gene [16]. Here we zoomed in on a 4.4 kb region around
the IVS1 variant and showed that the IVS1 allele comes in two
flavors: linked to either c.510C or c.510 T. We used allele-specific
PCR, which we find to be a useful approach to providing more de-
tailed information on haplotypes. The c.510CNT variant is synony-
mous, and we noted that its presence is often not included in
official DNA diagnostic reports, something that warrants manual ex-
amination and special attention in future reports. The fact that
c.510CNT has an allele frequency of 0.27 in the childhood-onset
IVS1 patients in our cohort indicates that it is a relatively frequent
variant within this population. Symptoms developed in childhood
in all 9/9 (100%) carriers of c.510CNT. This is relevant to regular diag-
nostics and to newborn screening programs, which are urgently
needed for predicting symptom onset and for deciding when ERT
treatment should be started in newly diagnosed late onset Pompe
disease (LOPD) patients [22]. Results from NBS programs indicate
that a new group of asymptomatic LOPD patients is coming into
being, and that among patients and their parents there is anxiety
and uncertainty regarding the timing of symptom onset and when
treatment with ERT will be necessary [31].
The exceptionally broad spectrum of symptom onset within com-
pound heterozygous IVS1 patients observed in many studies has rein-
forced the suspicion that there are modifying factors for Pompe
disease [2–13]. In theory, residual activity from the second allele could
explain clinical heterogeneity in compound heterozygous IVS1 patients.
This would potentially explain a later onset of symptoms. However, it
has been reported that in Pompedisease, the second allele is a null allele
in the far majority of cases [9,11,32]. This was confirmed in our cohort,
in which N90% of patient- including those in the group with adult
onset of symptoms- contained a fully deleterious variant on the second
allele. In addition, we showed a broad range of age at symptom onset in
a group of 57 patients with an identical GAA genotype (IVS1; c.525del)
(Suppl. Fig. S1C). Therefore, the second allele in compound heterozy-
gous IVS1 patients cannot explain the differences in age at symptom
onset observed in our cohort.
The median age at symptom onset for compound heterozygous
patients carrying c.510CNT was 2.5 years. However, we noted that
patients that contained c.510CNT showed some heterogeneity in
symptom onset that ranged from b1 to 14 years. Furthermore, not
all childhood-onset patients carried the c.510CNT variant. This
suggests that there are likely additional modifying factors. For exam-
ple, other SNVs might be present in cis with the GAA gene that mod-
ulate some aspect of GAA expression or GAA protein function such as
folding. We have analyzed a 4.4 kB region of genomic DNA around
IVS1 using allele-specific PCR, but it will be difficult with this ap-
proach to extend the analysis beyond this region due to the limita-
tions of the length of the PCR product that can be obtained. It will
be interesting to investigate this idea in the future. Although previ-
ous work has reported on the angiotensin-converting enzyme-PCR analysis ofGAA exons 1–3 of fibroblasts from a healthy control (WT) and a compound
icates theDNA sizemarker in base pairs (bp). Right: Cartoons of themajor splice products.
parts of exons: a pseudoexon in intron 1 (in red) or the C-terminal part of exon 2, which is
trons. Continuous lines represent splicing events. *: structural variant (see Suppl. Fig. S4).
xon 2 are also indicated. Numbered boxes represent canonical exons. The unnumbered
alysis of GAA exon 1 to 3 in fibroblasts from compound heterozygous IVS1 patients with
structural variant (see Suppl. Fig. S4). The patients or individuals analyzed are indicated
for the wildtype splice product N. (E) As (C), but now analyzed using RT-qPCR for the
n of SV2 and SV3 was too low to allow quantification. Data in d-e represent means ± SD
559A.J. Bergsma et al. / EBioMedicine 43 (2019) 553–561(ACE) I/D polymorphism and alpha actinin 3 (ACTN3) p.R577X poly-
morphism to be involved in disease onset [33], no such involvement
of the ACE I/D polymorphism was found in symptom onset in the
Dutch cohort of 131 patients or in a multicenter cohort from the
late-onset treatment study (LOTS) with 88 patients [34,35]. This
does indeed suggest that there are additional modifying factors.
We found that c.510CNT worsens the outcome of aberrant splicing
caused by the IVS1 variant. The IVS1 variantweakens the splice acceptor
of exon 2 to reduce the level of normal splicing (N) to 10–15%, and to in-
duce full skipping of exon 2 (SV2) or partial skipping (SV3) by utilizing a
cryptic splice acceptor in exon 2 [15,25,27,28]. We recently found that
the IVS1 variant induces utilization of a pseudoexon in intron 1 (SV5
and SV6) [29]. Antisense oligonucleotides (AONs) that prevented inclu-
sion of the pseudoexon were able to restore normal exon 2 splicing al-
most completely in the context of IVS1 [29,30]. The c.510CNT variant
did not affect utilization of the pseudoexon (data not shown). Instead,
it reduced leaky wild-type splicing (N) and utilization of the cryptic
splice site of exon 2 (SV3) (Fig. 3C–F, Fig. 4B–E, Suppl. Fig. S3B–D,
Fig. 5C and D). These results indicate that exon 2 splicing can be modu-
lated by sequences in exon 2 itself, aswell as in the intronic pseudoexon.
This is consistent with findings that showed that AONs directed at exon
2 sequences were also able to elevate normal splicing [36]. These find-
ings highlight the importance of diagnostic screening and the potentialFig. 4. c.510CNT is associated with symptom onset and worsening of splicing outcome in homo
(B) RT-PCR analysis ofGAA exon 1 to 3 in fibroblasts fromhomozygous IVS1 patients with andw
variant (see Suppl. Fig. S4). (C) Quantification using RT-qPCR of normal splicing (product N
homozygously, and one without c.510CNT. For comparison, expression in fibroblasts from a h
SV2 and SV3. In fibroblasts from healthy controls, SV2 and SV3 expression was undetectable a
GAA. Data in C-D and F represent means ± SD (n= 3 biological replicates).for development of new treatment strategies for variants involved in
splicing such as c.510CNT [37].
Although few symptomatic homozygous IVS1 patients have been
reported in the literature [11,17,19,20], a large number of compound
heterozygous IVS1 patients have been reported in Europe, with
many more in countries in North and South America, Australia and
New Zealand [2–13,23]. This suggests that many homozygous IVS1
patients remain asymptomatic, but that a subset develops symptoms
[11,19]. Due to NBS programs, the group of identified asymptomatic
individuals who are homozygous for IVS1 is increasing, bringing
challenges regarding the prediction of symptom onset and when to
start with ERT treatment that are similar to those described above
for the compound heterozygous IVS1 patients. In our cohort, 3/6
(50%) of symptomatic homozygous IVS1 patients carried c.510CNT,
andwhen c.510CNT was present, 3/3 (100%) of homozygous IVS1 pa-
tients developed symptoms. This indicates not only that c.510CNT
has a strong predictive value for symptom onset in homozygous
IVS1 patients, but also that there are probably additional modifying
factors for homozygous IVS1 patients. We also observed that the ef-
fects of c.510CNT on exon 2 splicing in patient-derived fibroblasts
were similar as in myoblasts obtained from muscle biopsies. This in-
dicates that c.510CNT modulates splicing via shared molecular tar-
gets, which is in line with the similar effects of the IVS1 variant onzygous IVS1 patients. (A) Genotypes and symptom onset in 10 homozygous IVS1 patients.
ithout c.510CNT. Products N, SV6, SV5, SV3 and SV2 are indicated on the right. *: structural
) in fibroblasts from two homozygous IVS1 patients, one carrying the c.510CNT variant
ealthy control is shown (individual 14). (D) As (C), but now of aberrant splice products
nd could not therefore be quantified. (E) Ratio of SV2 and SV3. (F) Enzymatic activity of
Fig. 5. c.510CNT worsens splicing outcome in skeletal muscle cells from compound heterozygous and homozygous IVS1 patients. (A) Flanking exon RT-PCR of GAA exon 2 in myoblasts.
Patient 16: compound heterozygous for IVS1, c.510CNT absent; Patient 4: compound heterozygous for IVS1, c.510CNT present on IVS1 allele; Patient 18: homozygous for IVS1, homozygous
for c.510CNT. Splice products N, SV6, SV5, SV3 and SV2 are indicated. *: structural variant (see Suppl. Fig. S4). Splice product N (normally spliced product) is highly expressed in patient 16
due to thepresenceof the c.2481+102_2646+31del variant on the second allele (which allowsnormal expression ofGAA productN). (B)Quantification of splice product Nusing RT-qPCR.
(C) Quantification of splice products SV2 and SV3. (D) Ratio of SV2 and SV3. (E) GAA enzymatic activity. Data in C-D and F represent means ± SD (n= 3 biological replicates).
560 A.J. Bergsma et al. / EBioMedicine 43 (2019) 553–561exon 2 splicing in fibroblasts and induced pluripotent stem cell-
derived skeletal muscle cells [29].
In conclusion, we report the identification of c.510CNT as a genetic
modifier of disease onset in patients with Pompe disease that are com-
pound heterozygous or homozygous for the common IVS1 GAA variant.
We recommend the following interpretation of newborn screening re-
sults and regular diagnostics: compound heterozygous IVS1 patients
who carry c.510CNT have the prognosis to develop symptoms at child-
hood. Compound heterozygous patients without c.510CNTmay develop
symptoms at any age. Homozygous IVS1 patients who carry c.510CNT,
either at heterozygous or at homozygous state, have the prognosis to
develop symptoms at any age, while homozygous IVS1 patientswithout
c.510CNT may remain asymptomatic or may develop symptoms at any
age. Future work should determine whether there are additional ge-
netic modifiers in cis or in trans with GAA, and, if so, how these may
modulate the clinical course of Pompe disease.
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